购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

FGTI-2734 mesylate (1247018-19-4 free base)

产品编号 T11282LCas号 2702297-24-1
别名 FGTI-2734 mesylate

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.

FGTI-2734 mesylate (1247018-19-4 free base)

FGTI-2734 mesylate (1247018-19-4 free base)

纯度: 无数据
产品编号 T11282L 别名 FGTI-2734 mesylateCas号 2702297-24-1

FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.

规格价格库存数量
5 mg¥ 3,010期货
10 mg¥ 5,560期货
50 mg¥ 17,035期货
100 mg¥ 29,785期货
200 mg 询价 期货
500 mg 询价 期货
1 mL x 10 mM (in DMSO)¥ 4,005期货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多
联系我们获取更多批次信息
资源下载
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.
靶点活性
GGT:520 nM , FT:250 nM
体外活性
FGTI-2734 mesylate (3-30 μM;?72 hours) inhibits both protein prenylation of HDJ2, RAP1A, KRAS and NRAS. FGTI-2734 mesylate (1-30 μM; 72 hours) induces apoptosis in mutant KRAS-dependent, but not mutant KRAS- independent, human cancer cells. ??FGTI-2734 inhibits KRAS membrane localization in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells.
体内活性
FGTI-2734 mesylate (intraperitoneally;?100 mg/kg/day for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors.
别名FGTI-2734 mesylate
化学信息
分子量606.73
分子式C27H35FN6O5S2
CAS No.2702297-24-1
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度信息
DMSO: 75 mg/mL (123.61 mM), Sonication is recommended.
溶液配制表
DMSO
1mg5mg10mg50mg
1 mM1.6482 mL8.2409 mL16.4818 mL82.4090 mL
5 mM0.3296 mL1.6482 mL3.2964 mL16.4818 mL
10 mM0.1648 mL0.8241 mL1.6482 mL8.2409 mL
20 mM0.0824 mL0.4120 mL0.8241 mL4.1204 mL
50 mM0.0330 mL0.1648 mL0.3296 mL1.6482 mL
100 mM0.0165 mL0.0824 mL0.1648 mL0.8241 mL

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

Related Tags: buy FGTI-2734 mesylate (1247018-19-4 free base) | purchase FGTI-2734 mesylate (1247018-19-4 free base) | FGTI-2734 mesylate (1247018-19-4 free base) cost | order FGTI-2734 mesylate (1247018-19-4 free base) | FGTI-2734 mesylate (1247018-19-4 free base) chemical structure | FGTI-2734 mesylate (1247018-19-4 free base) in vivo | FGTI-2734 mesylate (1247018-19-4 free base) in vitro | FGTI-2734 mesylate (1247018-19-4 free base) formula | FGTI-2734 mesylate (1247018-19-4 free base) molecular weight